Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

Table 6 Projected total and net clinical and cost outcomes for 10 provinces in Canada

	Alberta	British Columbia	Manitoba	New Brunswick	Newfoundland	Nova Scotia	Ontario	PEI	Quebec	Saskatchewan
Undiscounted lifetime cervical cancer cases
Vaccine A	223	71	23	8	6	11	269	2	208	11
Vaccine B	237	78	25	10	7	13	288	2	240	13
Difference (A- B)	−14	−8	−2	−2	−1	−2	−19	0	−32	−2
Undiscounted short-term budget impact (CAD)
Vaccine A	8 862 430	3 431 536	1 071 737	1 039 079	673 843	1 244 617	11 758 847	173 180	14 284 003	1 426 186
Vaccine B	8 862 430	3 431 536	1 071 737	1 039 079	673 843	1 244 617	11 758 847	173 180	14 284 003	1 426 186
Difference (A-B)	0	0	0	0	0	0	0	0	0	0
Discounted long-term budget impact (CAD)
Vaccine A	71 372 551	15 984 442	4 131 005	2 865 649	1 858 981	3 600 539	48 811 638	491 961	58 240 107	3 861 885
Vaccine B	72 015 197	16 091 773	4 155 215	2 890 712	1 874 203	3 630 560	49 128 834	495 873	58 720 943	3 894 102
Difference (A-B)	−642 645	−107 331	−24 210	−25 063	−15 222	−30 021	−317 196	−3 912	−480 836	−32 217

Short-term budget impact: Considers 1 year of vaccine purchase and administration costs.
Long-term budget impact: Considers lifetime costs to the health care system for the cohort of women eligible for vaccination in the 2011–12 school year. This includes both vaccinated and unvaccinated women.
CAD - Canadian dollars.
Vaccine A: HPV-16/18 AS04-adjuvanted vaccine.
Vaccine B: HPV-6/11/16/18 vaccine.
PEI – Prince Edward Island.

ISSN: 1471-2458